We're delighted to announce a new partnership with leading antibody manufacturer Vector Laboratories, Inc., using Etcembly's AI platform EMLy™ to develop novel immunotherapeutics.
Manufacturing problems such as poor yield and aggregation are significant issues in the development and production of antibody-based therapeutics.
In this partnership, we’ll be using EMLy's cutting edge structural modelling and generative AI capabilities to redesign existing non-proprietary antibodies, creating optimised variants with enhanced manufacturability and improved therapeutic outcomes.
Our CEO, Michelle Teng, says:
"We're excited to apply our AI-driven technology to Vector’s expertise in antibody engineering. This partnership will test different antibody variants and generate functional data, creating a powerful synergy that will advance cancer and autoimmune research."
Lisa V Sellers (Lisa V. S.) CEO of Vector Laboratories, adds:
"We’re excited to work with the Etcembly team to test optimized protein sequences and determine if their proprietary EMLy™ platform can enable us to improve them further for more effective therapies."
Want to learn more about this collaboration? Read the full press release here:
With the power of EMLy™, we’re transforming the future of protein engineering to deliver the next generation of immunotherapies. If you’re interested in working with us, get in touch here.
Hozzászólások